Earnings | Ionis Pharmaceuticals, Inc.

Skip to main navigation

Investors
Newsroom
Medical Professionals
Careers
- Intern Program
- Postdoctoral Program
Contact Us

Main navigation

About Us
Areas of Focus
Science & Innovation
Medicines
Patients & Advocacy

Media Center

Investor Relations

Overview
Investor News
Events
Stock Information
Financials
- SEC Filings
- Annual Reports
Governance
- Governance Documents
- Committee Composition
Investor Resources
Investor Email Alerts

Investor contact

Media contact

code

Earnings

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

Read more about Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Read more about Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Read more about Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Read more about Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Read more about Ionis reports third quarter 2025 financial results and highlights progress on key programs

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

Read more about Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

Ionis reports second quarter 2025 financial results and highlights progress on key programs

Read more about Ionis reports second quarter 2025 financial results and highlights progress on key programs

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Read more about Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Read more about Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis reports first quarter 2025 financial results

Read more about Ionis reports first quarter 2025 financial results

Pagination

Page 1
Next page

Subscribe to Earnings

Footer Navigation

Legal and Compliance:
Information For:
Explore:
Stay Connected:
- Contact Us
- LinkedIn
- X
- Instagram
- Facebook
- Community Guidelines

©1989 – 2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.